Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track NVS with free AI briefings, catalyst countdowns, and dilution alerts.

NVS · Novartis AG

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$8.9B Cash on Hand
CF+ Cash Runway
0.2% Short Interest
$157.1 Analyst Target (10)
Follow NVS by email Get an email when NVS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NVS, unsubscribe in one click. Privacy

📣 What NVS Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Inclisiran Sodium
FDA approved Dec 2021 · Leqvio
Percutaneous Coronary Intervention Phase 4 · NCT06909565 Recruiting
Iptacopan
FDA approved Dec 2023 · Fabhalta
Atypical Hemolytic Uremic Syndrome Phase 3 · NCT05795140 Recruiting
Remibrutinib
FDA approved Sep 2025 · Rhapsido
Relapsing Multiple Sclerosis Phase 3 · NCT05156281 Active not recruiting
Ribociclib
FDA approved Mar 2017 · Kisqali
Early Breast Cancer Phase 3 · NCT05827081 Active not recruiting
Asciminib
FDA approved Oct 2021 · Scemblix
Acute Lymphoblastic Leukemia Phase 1/2 · NCT07387926 Recruiting
Secukinumab
FDA approved Jan 2015 · Cosentyx
Psoriasis N/A · NCT02786186 Completed
Ansastrozole Early Breast Cancer Phase 3 · NCT05827081 Active not recruiting
Therapeutic Corticosteroid Primary Immune Thrombocytopenia (ITP) Phase 3 · NCT05653349 Active not recruiting
Leuprolide Early Breast Cancer Phase 3 · NCT05827081 Active not recruiting
Pacibekitug Myocardial Infarction Phase 3 · NCT07938411 Not yet recruiting
Pelabresib Hematologic Malignancy Phase 3 · NCT06401356 Recruiting
Ianalumab (VAY736) Primary Immune Thrombocytopenia (ITP) Phase 3 · NCT05653349 Active not recruiting
QMF149 Asthma Phase 3 · NCT05562466 Recruiting
Fluorouracil Metastatic Colorectal Cancer Phase 2 · NCT04952753 Terminated
Luxdegalutamide Metastatic Hormone-sensitive Prostate Cancer Phase 2 · NCT06991556 Active not recruiting
Vincristine Acute Lymphoblastic Leukemia Phase 1/2 · NCT07387926 Recruiting

Also used in these trials (approved or third-party drugs, not NVS's own candidates): Budesonide, Letrozole, Goserelin, Ruxolitinib, Teriflunomide, Everolimus, Exemestane, Methotrexate, Hydrocortisone, Tislelizumab, Darolutamide, Bevacizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

NVS holds $8.9B in cash and short-term investments and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NVS files for a raise →

👥 Who Owns NVS

Insiders 1.3% Institutions 10.6% Public and other holders 88.1%
HolderTypeShares% of sharesAs of
BlackRock, Inc. Institution (13G, 5%+) 145,227,650 7.61% 2026-09-30
NOVARTIS AG
10% owner
Insider 24,030,382 1.26% 2025-10-28
Fisher Asset Management, LLC Institution (13F) 16,762,528 0.88% 2026-09-30
Morgan Stanley Institution (13F) 8,437,223 0.44% 2026-09-30
Dimensional Fund Advisors LP Institution (13F) 7,875,541 0.41% 2026-09-30
Primecap Management Company Institution (13F) 6,585,464 0.35% 2026-09-30
LOOMIS SAYLES & CO L P Institution (13F) 4,834,120 0.25% 2026-09-30
Bank of America Corporation Institution (13F) 4,560,856 0.24% 2026-09-30
Goldman Sachs Group Inc Institution (13F) 3,296,470 0.17% 2026-09-30
JPMORGAN CHASE & CO Institution (13F) 2,548,730 0.13% 2026-09-30
Northern Trust Corporation Institution (13F) 2,532,827 0.13% 2026-09-30

Share count 1,908,151,679 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full NVS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NVS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.